Daily intake of β-cryptoxanthin prevents bone loss by preferential disturbance of osteoclastic activation in ovariectomized mice.
Although β-cryptoxanthin, a xanthophyll carotenoid, has been shown to exert an anabolic effect on bone calcification, little attention has been paid thus far to the precise mechanism of bone remodeling. Daily oral administration of β-cryptoxanthin significantly inhibited osteoclastic activation as well as reduction of bone volume in ovariectomized mice. In vitro studies revealed that β-cryptoxanthin inhibited differentiation and maturation of osteoclasts by repression of the nuclear factor-κB-dependent transcriptional pathway. Our results suggest that supplementation with β-cryptoxanthin would be beneficial for prophylaxis and for therapy of metabolic bone diseases associated with abnormal osteoclast activation.
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan.
Kakeru
K
Ozaki
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan.
Maika
M
Okamoto
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan.
Kazuya
K
Fukasawa
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan.
Takashi
T
Iezaki
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan.
Yuki
Y
Onishi
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan.
Yukio
Y
Yoneda
Citrus Research Division, NARO Institute of Fruit Tree Science, National Agriculture and Food Research Organization, Shimizu, Shizuoka, Japan.
Minoru
M
Sugiura
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan. Electronic address: hinoi@p.kanazawa-u.ac.jp.
Eiichi
E
Hinoi
D000284:Administration, Oral; D000818:Animals; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000517:prevention & control*; D002454:Cell Differentiation / Q000187:drug effects*; D002957:Citrus; D065366:Cryptoxanthins / Q000008:administration & dosage* / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D016328:NF-kappa B / Q000502:physiology; D010010:Osteoclasts / Q000166:cytology* / Q000187:drug effects*; D010052:Ovariectomy; D064167:Recommended Dietary Allowances; D015398:Signal Transduction / Q000187:drug effects
D065366:Cryptoxanthins; D016328:NF-kappa B
Osteoblast; Osteoclast; Osteoporosis